Libyan Open University Journal of Medical Sciences and Sustainability
(https://oujournals.ly/index.php/LOUJMSS/index)
Volume 2 - Issue 1 - 2026 - Pages 17-30

Drug-food interactions: Risk assessment and clinical management strategies to enhance medication safety

Ali Zaid Ashour *
Tripoli College of Medical Sciences - Tripoli, Libya
Sabratha Teaching Hospital - Sabratha, Libya
* **Email for reference researcher**: alielzar98@gmail.com

Received: 11-01-2026; Accepted: 08-03-2026; Published: 26-03-2026

Abstract
Drug-food interactions can change medicine exposure and clinical response. They can cause toxicity or treatment failure. Medication safety needs structured risk assessment and practical management steps. This paper reviews mechanisms and real, publicly available evidence. We used open full texts and regulator materials. We searched PubMed Central, DailyMed labels, and national safety alerts. We included crossover trials, prospective cohorts, and controlled laboratory digestion models. We extracted effect size, risk factors, and clinical advice statements. A crossover trial found grapefruit juice increased simvastatin exposure. Simvastatin AUC rose 3.6-fold in ten volunteers. Apple juice reduced fexofenadine exposure in a volume-dependent pattern. AUC ratios fell to 0.59 with 300 mL and 0.39 with 600 mL. A prospective cohort linked vitamin K intake patterns to poor warfarin control. Moderate vitamin K intake had the lowest predicted risk of low PTTR. Food increases rivaroxaban exposure at 15-20 mg doses. Product information reports a mean AUC rise of 39% with food. Tea consumed near levothyroxine dosing linked to higher TSH. Avoiding tea and coffee near dosing reduced TSH after three months. We propose a practical risk matrix. It uses interaction magnitude, drug vulnerability, and monitoring ease. We then give clinical strategies for prescribing, counselling, and follow-up. The approach supports safer therapy in community and hospital settings.

Keywords: drug-food interactions; medication safety; risk assessment; pharmacokinetics; pharmacodynamics; patient counselling; pharmacovigilance.

Background
Drug-food interactions arise from physical, chemical, or physiological relationships. These relationships change drug exposure or drug effect. Interactions can be pharmacokinetic or pharmacodynamic. Pharmacokinetic changes affect absorption, distribution, metabolism, or excretion. Pharmacodynamic changes alter the clinical effect at the target site.

Modern care often combines medicines with meals and drinks. This can support adherence. It can also create avoidable harm. Reviews describe enzyme inhibition and transporter modulation as key pathways. Transporter effects can reduce drug exposure, not increase it. This creates loss of effect, not toxicity.

Medication safety is a global public health focus. The World Health Organization launched "Medication Without Harm". The initiative aims to reduce severe avoidable medication-related harm by 50% in five years. The program highlights polypharmacy and care transitions as risk areas.

Food-drug interactions are often missed in routine work. A cross-sectional study in Ethiopia found low knowledge scores among healthcare professionals. Many participants struggled with timing of dosing relative to meals. Training exposure was rare in that sample.

Regulators address food effects in labels and safety updates. Examples include warnings on grapefruit juice and simvastatin. Another example is the instruction to take rivaroxaban 15 mg and 20 mg with food. National alerts report suspected lack of efficacy with fasting intake.

Copyright: © 2026 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Methods

This paper used a targeted evidence synthesis. The goal was practical clinical use. It focused on public studies with extractable figures. It also used regulator product information.

Sources were limited to open or official materials. PubMed Central articles were prioritized for reproducibility. DailyMed was used for labelling statements. Regulator notices were used for risk communication examples. Key regulator sources included the U.S. Food and Drug Administration and the European Medicines Agency.

Eligibility focused on real-world usable evidence. Human crossover trials and prospective cohorts were included. Controlled laboratory simulations were included when clinically linked. Each included study needed explicit methods and quantified outcomes. Each selected figure needed a stable download path.

Data extraction focused on magnitude and direction. We recorded AUC changes, Cmax changes, or clinical markers. We also recorded label wording on food timing. We then mapped each interaction to a risk assessment template.

Evidence base from publicly available experiments

Evidence map and mechanism categories

Most clinically relevant interactions fit into a few classes. Some interactions increase exposure by enzyme inhibition. Some interactions decrease exposure by uptake transporter inhibition. Some interactions reduce absorption by chelation or binding. Some interactions require food to increase absorption. Some interactions alter pharmacodynamics, such as vitamin K with warfarin.

Table 1 Mechanism classes and clinical pattern.

Mechanism class	Typical direction	Example pair	Primary risk	Measurement commonly used
Intestinal enzyme inhibition	Exposure rises	Grapefruit juice + simvastatin	Toxicity risk rises	AUC, Cmax
Uptake transporter inhibition	Exposure falls	Apple juice + fexofenadine	Loss of effect	AUC, clinical response
Chelation or binding in gut	Exposure falls	Dairy calcium + ciprofloxacin	Treatment failure	AUC, clinical endpoints
Food-dependent absorption	Exposure rises with food	Rivaroxaban 20 mg + meal	Under-dosing if fasting	AUC, Cmax
Pharmacodynamic antagonism	Effect falls	Vitamin K foods + warfarin	INR instability	INR, PTTR

Grapefruit juice increasing statin exposure

A human crossover trial tested grapefruit juice with simvastatin. Ten healthy volunteers were studied. Participants took grapefruit juice 200 mL daily for three days. A single 40 mg dose of simvastatin was given on day three. Simvastatin AUC rose 3.6-fold with grapefruit juice. Simvastatin acid AUC rose 3.3-fold. Cmax rose 3.9-fold for simvastatin and 4.3-fold for simvastatin acid.

Copyright: © 2026 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Libyan Open University Journal of Medical Sciences and Sustainability
(https://oujournals.ly/index.php/LOUJMSS/index)
Volume 2 - Issue 1 - 2026 - Pages 17-30



Figure 1 Mean simvastatin and simvastatin acid concentrations after 40 mg simvastatin. Grapefruit juice was taken once daily for three days. Source: Jari J Lilja et al. (2004)

Clinical meaning is direct. Raised exposure can increase muscle toxicity risk. Labels warn against grapefruit juice with simvastatin. DailyMed states grapefruit juice can raise simvastatin plasma levels. The label links this to myopathy and rhabdomyolysis risk.

Risk also differs across patients. A review describes large variability in grapefruit interactions. The review links variability to baseline intestinal CYP3A4 levels. It also notes prolonged effect due to enzyme inactivation.

Copyright: © 2026 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Libyan Open University Journal of Medical Sciences and Sustainability
(https://oujournals.ly/index.php/LOUJMSS/index)
Volume 2 - Issue 1 - 2026 - Pages 17-30

Grapefruit juice effects on CYP3A4 and exposure over time

A mechanistic review in the British Journal of Clinical Pharmacology describes the grapefruit pathway. It reports grapefruit juice reduces small bowel CYP3A4 content. It reports a 62% mean reduction after five days intake. The review links this to a greater than 3-fold felodipine AUC rise. It also notes a prolonged effect because new enzyme synthesis is needed.

The review also provides a cross-drug table. It lists several medicines and typical exposure changes. The table groups drugs by baseline bioavailability. It reports high relative AUC and Cmax rises for several CYP3A4 substrates.

Table 2 Summary table of relative AUC and Cmax changes with grapefruit juice across studied drugs. Source: David G Bailey et al. (1998).

Bioavailability	*Medication*	*Drug AUC*	*Drug C_{max}*
< 5%	Nisoldipine [19]	**198**	**406**
	Nimodipine [20]	**151**	124
	Terfenadine [54–57]	249	343
	Saquinavir [73]	**150–220**	—
15–20%	Felodipine [5, 8, 12, 14–18]	**145–345**	**170–538**
	Nicardipine [21]	**134–196**	**125–153**
	Nitrendipine [22, 23]	**140–206**	140–199
	Propafenone [79]	133	123
	17β-oestradiol [82]	116	131
30–40%	Cyclosporin [65–71]	108–162	104–132
	Diltiazem [80]	110	102
	Ethinylestradiol [81]	128	137
	Midazolam [62]	**152**	**156**
	Triazolam [63]	**148**	**130**
	Verapamil [34]	**143**	**161**
60%	Nifedipine [12, 24–26]	**134–203**	104–194
70%	Quinidine [75]	108	93
> 80%	Acenocoumarol [74]	98	—
	Amlodipine [27, 28]	108–116	115
	Prednisone [69]	150	139
	Theophylline [76]	103	97

Statistically significant increases in drug AUC and C_{max} are indicated in bold. All medications are substrates for CYP3A4 except for prednisone and theophylline.

Clinical takeaway is risk stratification. Low oral bioavailability drugs can show larger proportional change. The same review highlights dihydropyridines and specific CNS sedatives. It also notes within-person reproducibility. This supports patient-specific counselling.

Fruit juices reducing exposure by uptake transporter inhibition

Grapefruit juice does not always increase exposure. A later review describes a “new type” interaction. It involves inhibition of uptake transporters like OATP1A2. This reduces oral absorption for some drugs. The review describes fexofenadine as a probe drug.

Copyright: © 2026 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

The review reports a pilot study in two volunteers. Fexofenadine was given with water or grapefruit juice 300 mL. Plasma concentrations were lower with grapefruit juice in both subjects. Reported AUC and Cmax values were lower with grapefruit.



Figure 2 Pilot plasma concentration-time profiles for two subjects. Grapefruit juice reduced exposure versus water. Source: Bailey (2010)

The same review reports a volume-effect relationship idea. It also reports a time window for avoid-ability. It states inhibition lasted more than 2 hours but less than 4 hours. This supports spacing juice and drug intake.

Labelling reflects this risk for fexofenadine. DailyMed states fruit juices can reduce bioavailability and exposure. It recommends taking fexofenadine with water to maximise effect. It also notes grapefruit, orange, and apple juices.

Apple juice volume and fexofenadine exposure

A controlled human crossover trial tested apple juice volumes with fexofenadine. Ten healthy subjects took fexofenadine 60 mg. Apple juice volumes were 150 mL, 300 mL, and 600 mL.

Copyright: © 2026 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Water was the control condition. AUC ratios were 0.903 for 150 mL. AUC ratios were 0.593 for 300 mL. AUC ratios were 0.385 for 600 mL.



Figure 3 Plasma fexofenadine concentration profiles after water or apple juice. The reduction increased with juice volume. Source: J Luo et al. (2016).



Figure 4 Individual AUC0-∞ values across water and apple juice volumes. A consistent decline is visible with higher volumes. Source: Luo et al. (2016).

This evidence supports a dose-timing rule. Small volumes may be less meaningful. Large volumes may be clinically relevant. Trial authors suggested 150 mL could be within a bio comparability bound.

Copyright: © 2026 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Libyan Open University Journal of Medical Sciences and Sustainability
(https://oujournals.ly/index.php/LOUJMSS/index)
Volume 2 - Issue 1 - 2026 - Pages 17-30

Vitamin K intake and warfarin control during initiation

Warfarin is a high-risk medicine. Diet intake can change response. A prospective cohort study assessed vitamin K intake during initiation. It used a validated 7-day food diary. It assessed low PTTR as outcome. The cohort analyzed 282 patients who returned diaries. The study found the second quartile had best control. It reported the lowest adjusted predicted probability for low PTTR at 0.36.



Figure 5 Predicted probability of low PTTR during warfarin initiation. Moderate intake quartile had lowest risk. Source: Ron C Li et al. (2013).

Clinical advice usually stresses consistency. DailyMed advises a normal balanced diet with consistent vitamin K. It warns against drastic diet changes and high leafy greens intake. This supports consistency rather than elimination.

A UK hospital dietetics leaflet gives similar guidance. It states vitamin K foods should not be excluded. It stresses stable intake patterns. It also supports general healthy eating.

Food required for absorption: rivaroxaban

Some drugs need food for adequate absorption. Rivaroxaban has a known food effect at higher doses. The EMA product information states a 20 mg tablet has 66% bioavailability fasting. It reports mean AUC increases of 39% with food. It recommends 15 mg and 20 mg doses be taken with food.

National safety communication mirrors this. The Medicines and Healthcare products Regulatory Agency reports suspected lack of efficacy when taken fasting. It advises reminders to take 15 mg or 20 mg with food. It also gives advice on crushing tablets with apple puree, followed by food.

A cross-study modelling analysis examined meal timing and content. It used data from clinical development studies. It concluded meal timing and meal content did not materially affect 20 mg PK. It still confirmed food is needed for high bioavailability.

Copyright: © 2026 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Libyan Open University Journal of Medical Sciences and Sustainability
(https://oujournals.ly/index.php/LOUJMSS/index)
Volume 2 - Issue 1 - 2026 - Pages 17-30



Figure 6 Box plots of estimated and simulated exposures for 20 mg dosing across datasets. Source: Liping Zhang et al. (2017)

Tea and coffee timing with levothyroxine

Levothyroxine has timing-sensitive absorption. A DailyMed label instructs dosing on an empty stomach. It recommends taking it one-half to one hour before breakfast. It also describes spacing from absorption-interfering agents.

A prospective cohort study assessed tea and coffee use near dosing. It recruited 37 hypothyroid patients. Patients had tea and or coffee within one hour of dosing. They then avoided tea and coffee around dosing for three months. TSH decreased after the change in all groups.



Figure 7 Patient-level TSH trajectories across coffee-only, tea-only, and combined groups. Source: Ying-Wen Lai and Huang (2022).

Copyright: © 2026 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

The same study asked patients to separate consumption by at least four hours. That is an intensive spacing rule. It fits high-sensitivity medicines. Labelling also supports reviewing dose needs when foods are taken near dosing.

Binding and chelation: bisphosphonates and food models

Food can bind drugs and reduce free fraction. This can reduce absorption. A Pharmaceutics study tested risedronate with common food products. It used simulated intestinal and gastric fluids. It also used simulated chyme and a needle device. It compared food types by sorption and availability.

The study includes graphs of risedronate availability over time. It shows large differences across food products. It reports egg white and white bread had lower impact than cheese.



Figure 8 In vitro risedronate availability after contact with foods during simulated digestion. Source: Monika Zielińska et al. (2022).

This evidence supports strict fasting advice seen in practice. It also supports why "take with water only" is common. It also shows how food composition matters, not just food presence.

Label-based evidence for chelation and reduced absorption

Chelation is a well-known pathway for some antibiotics. Ciprofloxacin labelling includes a clear instruction. DailyMed states it should not be taken with dairy products alone. It also includes calcium-fortified juices in the warning. It allows use with a meal containing these products.

This label statement matches mechanism reviews. Reviews discuss divalent cations forming chelates with fluoroquinolones. The result is lower absorption and possible failure.

Risk assessment

- **Why risk assessment needs more than a list**

A simple "avoid" list is not enough. Interaction magnitude differs by patient and food pattern. Risk also depends on drug vulnerability and monitoring access. A pharmacovigilance review argues for integrated risk management. It emphasizes under-recognition and under-reporting. It calls for frameworks linking evidence to labelling and surveillance.

Copyright: © 2026 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Risk assessment should separate potential from expected harm. It should also separate toxicity risk from failure risk. Grapefruit illustrates both directions. Simvastatin exposure rises with grapefruit juice. Fexofenadine exposure can fall with fruit juices.

- **A practical clinical risk rubric**

This paper proposes a four-domain rubric. Each domain can be scored 0-2. Higher scores mean higher risk. The rubric supports consistent documentation. It also supports prioritized counselling. It matches risk themes in global medication safety work.

Table 3 Drug-food interaction risk rubric for clinical use.

Domain	Score 0	Score 1	Score 2
Interaction magnitude	<25% AUC change	25-100% AUC change	>2-fold AUC change
Drug vulnerability	Wide safety margin	Moderate margin	Narrow margin or high-risk drug
Food exposure pattern	Rare or avoidable	Regular but changeable	Daily and culturally embedded
Monitoring and detectability	Easy lab marker	Some monitoring	Hard to detect early

The rubric should be used with a brief "risk narrative". The narrative should state direction and outcome. Direction can be "toxicity" or "loss of effect". Outcome should be a patient-relevant event. Examples include bleeding, thrombosis, infection persistence, or symptom relapse.

- **Interaction documentation and prioritization**

Risk control requires systematic medication history. Food and drinks must be part of the history. Medication reconciliation can support this process. An NCBI patient safety chapter describes reconciliation. It frames reconciliation as comparing orders to what patients take. It aims to avoid omissions, duplications, dosing errors, and interactions. It recommends use at each transition of care.

A professional toolkit also supports comprehensive lists. The International Pharmaceutical Federation toolkit includes prescription and non-prescription medicines. It also includes vitamins and mineral supplements. This supports systematic capture of interaction drivers.

Clinical management strategies

- **Core management principles**

Clinical management should follow a consistent logic. First, identify high-risk pairs. Second, confirm mechanism and direction. Third, decide avoidance or timing separation. Fourth, monitor outcomes and adjust dose when needed. This aligns with risk management themes in food-drug pharmacovigilance work.

Patient counselling should be concrete and measurable. "Avoid grapefruit" is measurable. "Take with water" is measurable. "Keep vitamin K steady" is measurable. Vague messaging reduces adherence and learning.

- **Drug-specific management actions from evidence and labels**

Table 4 Evidence-based counselling statements aligned to regulators and trials.

Drug	Food or drink issue	Practical instruction	Evidence base
Simvastatin	Grapefruit juice	Avoid grapefruit and grapefruit juice	Label warning and crossover trial
Fexofenadine	Fruit juices	Take with water, avoid grapefruit/orange/apple juice near dosing	Label warning and PK trials

Copyright: © 2026 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Warfarin	Vitamin K foods	Maintain consistent vitamin K intake	Label warning and cohort evidence
Rivaroxaban 15-20 mg	Fasting intake	Take with food or a meal	EMA product info and MHRA safety update
Levothyroxine	Tea/coffee near dosing	Take on empty stomach, separate from tea/coffee	Label timing advice and cohort study
Ciprofloxacin	Dairy or calcium juices alone	Do not take with dairy alone	Label instruction

- **Timing strategies and when they work**

Timing separation is useful when the effect is short-lived. The fruit juice uptake transporter review describes a short inhibition window. It suggests avoid-ability with spacing. It reports inhibition lasting more than 2 hours but less than 4 hours. This supports spacing juice consumption from dosing.

Timing separation is less reliable for irreversible enzyme inhibition. Grapefruit effects on CYP3A4 can persist. The grapefruit review estimates a prolonged effect window. It notes a half-life of effect around 12 hours. It still shows effects after 24 hours in some cases. This limits timing-only solutions for high-risk drugs.

Some drugs need food to reach exposure targets. In that case, timing separation is the opposite. The dose should be linked to a meal. The EMA notes rivaroxaban 15mg and 20mg should be taken with food. The MHRA safety update supports this due to efficacy concerns.

- **Monitoring and follow-up plans**

Monitoring should match the interaction type. Warfarin needs INR monitoring and diet review. Early therapy is high-risk for unstable INR. The cohort evidence emphasizes initiation phase risk. Consistent vitamin K intake supports stable response.

Levothyroxine needs thyroid function monitoring after habit change. The tea and coffee cohort study used a three-month period. It recorded changes in TSH, T3, and T4 after stopping tea and coffee near dosing. This supports lab reassessment after diet timing changes.

Direct oral anticoagulants have limited routine lab measures. Prevention relies more on adherence and dosing rules. Official guidance stresses taking rivaroxaban 15-20 mg with food. Safety updates note suspected thromboembolic events with fasting intake.

- **System-level interventions**

Drug-food interaction control needs system supports. The WHO initiative highlights medication systems and human factors. It links errors to prescribing, dispensing, and monitoring steps. It calls for stakeholder mobilization and sustained action.

Transitions of care are a high-risk point. Medication reconciliation reduces discrepancies at transitions. An NCBI chapter recommends reconciliation at every transition. It includes setting and practitioner changes. It targets interaction risk alongside other error types.

Decision support often under-alerts for food interactions. Education and structured prompts can help. Surveys show knowledge gaps across professions. Pharmacists often score higher than other groups. The gaps support training and workflow integration.

- **Patient-facing materials and safe communication**

Patient materials should use examples tied to daily habits. Regulators provide examples like grapefruit and fexofenadine. An FDA consumer update explains transporter-based reduced absorption. It highlights why grapefruit can decrease some drugs. It also restates label advice for fexofenadine.

Copyright: © 2026 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

UK-facing advice should reference national sources. The National Institute for Health and Care Excellence BNF interaction page lists grapefruit-simvastatin as severe. It states the manufacturer advises avoidance. This supports consistent UK counselling.

Discussion

Evidence shows drug-food interactions can be large and clinically relevant. Grapefruit juice increased simvastatin exposure several-fold in a controlled trial. Apple juice lowered fexofenadine exposure in a dose-dependent pattern. Vitamin K intake patterns predicted warfarin control during initiation. Food was required for full rivaroxaban exposure at high doses. Tea and coffee timing affected levothyroxine control in a cohort.

These results point to two safety modes. One mode is overdose risk from higher exposure. Grapefruit with simvastatin fits this mode. Another mode is therapeutic failure from lower exposure. Fruit juice with fexofenadine fits this mode. Fasting rivaroxaban intake also fits this mode. Risk frameworks must cover both directions.

Diet advice must be realistic. Strict elimination messages can fail. Consistency advice may be more usable for vitamin K. The warfarin cohort suggests moderate intake can be beneficial early. Labels and hospital leaflets stress stable intake patterns.

This paper has limits. It focused on open studies with downloadable figures. It did not cover all interaction pairs. Some evidence is label-based, not trial-based. Still, labels embed regulator review of evidence. The selected set covers key mechanism classes with measurable outcomes.

Conclusion

Drug-food interactions remain a major concern in safe medication use. Many patients take medicines with daily meals. This raises the chance of unwanted effects or reduced drug action. This paper showed that these interactions occur through many pathways. These include changes in absorption, metabolism, and excretion. Enzyme systems like CYP3A4 play a strong role. Transport proteins also affect drug levels in the body.

The review also showed that some foods can increase drug toxicity. Others can lower the drug effect. Grapefruit juice, dairy products, and vitamin K rich foods are common examples. Clinical studies and real case reports confirm these risks. These findings support the need for careful monitoring in practice.

Risk assessment tools can help identify patients at higher risk. These include elderly patients and those on many drugs. Clear patient counseling also plays a key role. Simple advice about food timing can improve treatment results. Healthcare providers must guide patients in a clear and simple way.

The paper also discussed management strategies. These include dose adjustment, timing changes, and alternative drug choices. Clinical guidelines support these steps. Digital tools and alert systems can also reduce errors. Future work should focus on better prediction models. More real-world data is needed to improve safety. Education programs can also raise awareness among patients and clinicians.

References

1. Advinha, A. M., Fernandes, J. P., & Perdigão, M. (2024). Food-drug interactions risk management: An emergent piece of pharmacovigilance systems. *Pharmacology Research & Perspectives, 12*(4), e1245. https://doi.org/10.1002/prp2.1245
2. Bailey, D. G., Malcolm, J., Arnold, O., & Spence, J. D. (1998). Grapefruit juice-drug interactions. *British Journal of Clinical Pharmacology, 46*(2), 101-110. https://doi.org/10.1046/j.1365-2125.1998.00764.x
3. Bailey, D. G. (2010). Fruit juice inhibition of uptake transport: A new type of food-drug interaction. *British Journal of Clinical Pharmacology, 70*(5), 645-655. https://doi.org/10.1111/j.1365-2125.2010.03722.x

Copyright: © 2026 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

4. Balaban, U., et al. (2025). Assessment of food-drug interaction knowledge among Turkish healthcare professionals. *BMC Medical Education*.
5. Choi, J. H., & Ko, C. M. (2017). Food and drug interactions. *Journal of Lifestyle Medicine, 7*(1), 1-9. https://doi.org/10.15280/jlm.2017.7.1.1
6. Degefu, N., et al. (2022). Knowledge of drug-food interactions among healthcare professionals working in public hospitals in Ethiopia. *Journal of Multidisciplinary Healthcare*.
7. Lilja, J. J., Neuvonen, M., & Neuvonen, P. J. (2004). Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. *British Journal of Clinical Pharmacology, 58*(1), 56-60. https://doi.org/10.1111/j.1365-2125.2004.02095.x
8. Luo, J., Imai, H., Ohyama, T., et al. (2016). The pharmacokinetic exposure to fexofenadine is volume-dependently reduced in healthy subjects following oral administration with apple juice. *Clinical and Translational Science, 9*(4), 201-206. https://doi.org/10.1111/cts.12400
9. Li, R. C., Finkelman, B. S., Chen, J., et al. (2013). Dietary vitamin K intake and anticoagulation control during the initiation phase of warfarin therapy: A prospective cohort study. *Thrombosis and Haemostasis, 110*(1), 195-196. https://doi.org/10.1160/TH13-02-0111
10. Lai, Y.-W., & Huang, S.-M. (2022). Tea consumption affects the absorption of levothyroxine. *Frontiers in Endocrinology, 13*, 943775. https://doi.org/10.3389/fendo.2022.943775
11. Takanaga, H., Ohnishi, A., Matsuo, H., et al. (2000). Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. *British Journal of Clinical Pharmacology, 49*(1), 49-58. https://doi.org/10.1046/j.1365-2125.2000.00140.x
12. Zhang, L., Peters, G., Haskell, L., et al. (2017). A cross-study analysis evaluating the effects of food on the pharmacokinetics of rivaroxaban in clinical studies. *Journal of Clinical Pharmacology, 57*(12), 1607-1615. https://doi.org/10.1002/jcph.958
13. European Medicines Agency. (n.d.). *Xarelto, INN-rivaroxaban: EPAR product information*. https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf
14. Aejeeliyah Yousuf (2025). Antibiotic Resistance Trends in Hospital Settings: A 5-Year Cross-Sectional Analysis from Clinical Isolates. Journal of Insights in Basic and Applied Sciences, 1(1), 20-26.
15. Medicines and Healthcare products Regulatory Agency. (2019, July 17). *Rivaroxaban (Xarelto▼): reminder that 15 mg and 20 mg tablets should be taken with food*. https://www.gov.uk/drug-safety-update/rivaroxaban-xarelto-reminder-that-15-mg-and-20-mg-tablets-should-be-taken-with-food
16. National Institute for Health and Care Excellence. (n.d.). *BNF interactions: Grapefruit*. https://bnf.nice.org.uk/interactions/grapefruit/
17. U.S. Food and Drug Administration. (2021, July 1). *Grapefruit juice and some drugs don't mix*. https://www.fda.gov/consumers/consumer-updates/grapefruit-juice-and-some-drugs-dont-mix
18. World Health Organization. (2017). *Medication Without Harm (Global Patient Safety Challenge overview page)*. https://www.who.int/publications/i/item/WHO-HIS-SDS-2017.6
19. World Health Organization. (n.d.). *Medication Without Harm (initiative page)*. https://www.who.int/initiatives/medication-without-harm
20. DailyMed. (n.d.). *Fexofenadine hydrochloride tablet, film coated: label information*. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9738127d-7308-454c-94c8-3229d507370f
21. DailyMed. (n.d.). *Levothyroxine sodium tablets: label information*. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ddcaec1-a58f-340b-9bc1-bbe048b8c885
22. DailyMed. (n.d.). *Warfarin sodium tablets: label information*. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=558b7a0d-5490-4c1b-802e-3ab3f1efe760
23. DailyMed. (n.d.). *Ciprofloxacin tablets: label information*. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fbcd32c0-bcfd-4cc7-8e81-6612bc0cfc45
24. Nusaiba Abduladim Elmahjub (2025). Global Trends in Prescription Drug Utilization and Resistance Patterns: A 15-Year Comparative Study of Therapeutic Practices. Scientific Journal for Publishing in Health Research and Technology, 1(1), 26-34.
25. Global Trends in Cardiovascular Mortality and Risk Factors: Insights from WHO and Global Burden of Disease Data. (2025). *Libyan Open University Journal of Medical Sciences and Sustainability*, *1*(1), 28-36.
26. Hamza Khalifa Ibrahim. (2025). Impact of Ultra-Processed Food and Sugar-Sweetened Beverage Consumption on Type 2 Diabetes Risk in Young Adults. Libyan Journal of Health, Science, and Development (LJHSD), 1(1), 01-07.

Copyright: © 2026 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

27. Aejeeliyah Yousuf (2025). Assessment of Antibiotic Resistance Trends Across Regions Through a 10 Year Retrospective Data Analysis. Scientific Journal for Publishing in Health Research and Technology, 1(1), 17-25.
28. Hamza Khalifa Ibrahim (2025). Adverse Drug Reactions in Polypharmacy: A Real-World Pharmacovigilance Study Using EHR Data. (2025). Journal of Insights in Basic and Applied Sciences, 1(1), 10-19.
29. Nabil Saad Miftah (2025). Pharmacovigilance and Adverse Drug Reaction Patterns: A Data-Driven Study on Drug Safety in Clinical Practice. Journal of Insights in Basic and Applied Sciences, 1(1), 27-34.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of **LOUJMSS** and/or the editor(s). **LOUJMSS** and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Copyright: © 2026 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).